SHANGHAI, Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent for WuXiBodyTM – a proprietary, highly flexible engineering platform that greatly enhances the developability characteristics of bispecifics – was granted by the U.S.

2024年1月16日，全球领先的合同研究、开发和制造组织（CRDMO）无锡生物（“无锡生物”）（2269.HK）今天宣布，美国授予了WuXiBodyTM专利，WuXiBodyTM是一种专有的、高度灵活的工程平台，可大大增强双特异性的可开发性。

Patent and Trademark Office. This also marks that WuXiBodyTM has been granted patents in the U.S., Japan and China..

专利商标局。这也标志着WuXiBodyTM已在美国、日本和中国获得专利。。

WuXiBodyTM has been widely adopted globally since its launch in 2018. It can effectively break through the CMC barriers for the development of many bispecific antibodies with high expression yield, high stability, good solubility, and easy purification to homogeneity. Additionally, it can shorten the process by 6-18 months and significantly reduce manufacturing costs compared to many other current bispecific platforms..

WuXiBodyTM自2018年推出以来，已在全球广泛采用。它可以有效地突破CMC障碍，开发出许多双特异性抗体，具有高表达率，高稳定性，良好的溶解度，易于纯化至均一性。此外，与许多其他当前的双特异性平台相比，它可以将流程缩短6-18个月，并显着降低制造成本。。

The WuXiBodyTM platform enables almost any mAb sequence pairs to be assembled into bispecific constructs that are expected to have low immunogenicity risk and a long in vivo half-life. It offers unique structural flexibility, which makes it convenient for building various formats with different combinations of valencies (1+1, 1+2, 2+2), and is also compatible with different Fc domains to meet the requirements of different target biologies..

WuXiBodyTM平台能够将几乎任何mAb序列对组装成双特异性构建体，预期其具有低免疫原性风险和长的体内半衰期。它提供了独特的结构灵活性，这使得它可以方便地构建具有不同化合价组合（1+1、1+2、2+2）的各种格式，并且还与不同的Fc域兼容，以满足不同目标生物学的要求。。

Dr. Chris Chen, CEO of WuXi Biologics, commented, 'We're proud that our WuXiBodyTM platform was granted the U.S. patent, further validating our global leadership in bispecific technologies and capabilities. It is a great milestone for our Discovery business, which will enable more partners to pursue different biology and therapeutic approaches via this novel bispecific antibody platform.

无锡生物制品首席执行官克里斯·陈博士评论道：“我们为我们的WuXiBodyTM平台获得美国专利感到骄傲，这进一步验证了我们在双特异性技术和能力方面的全球领先地位。这是我们发现业务的一个伟大里程碑，它将使更多合作伙伴能够通过这种新型双特异性抗体平台寻求不同的生物学和治疗方法。

We will continue to invest in next-generation technologies to provide new biologics solutions for our global partners and benefit patients worldwide.'.

我们将继续投资于下一代技术，为我们的全球合作伙伴提供新的生物制剂解决方案，并使全球患者受益。”。

As of December 31, 2023, there are 45 out-licensed WuXiBodyTM projects in various stages -- four of which are in Phase Ⅰ clinical development. Further demonstrating the value of WuXiBodyTM's state-of-the-art technology, investigational New Drug (IND) applications of two WuXiBodyTM projects are expected be approved in 2024..

截至2023年12月31日，有45个已获得许可的WuXiBodyTM项目处于不同阶段，其中四个处于Ⅰ期临床开发阶段。两个WuXiBodyTM项目的研究性新药（IND）应用预计将于2024年获得批准，这进一步证明了WuXiBodyTM最先进技术的价值。。

About WuXi Biologics

无锡生物制品简介

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide..

无锡生物制品（股票代码：2269。HK）是一家领先的全球合同研究、开发和制造组织（CRDMO），提供端到端的解决方案，使合作伙伴能够发现、开发和制造生物制品，从概念到商业化，造福全世界的患者。。

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing..

无锡生物制品有限公司在中国、美国、爱尔兰、德国和新加坡拥有12000多名熟练员工，利用其技术和专业知识为客户提供高效、经济的生物制品发现、开发和制造解决方案。截至2023年12月31日，无锡生物制品有限公司正在支持698个综合客户项目，其中包括24个商业制造项目。。

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability..

无锡生物将环境、社会和治理（ESG）责任视为我们的企业精神和商业战略的组成部分，我们的目标是成为生物制品CRDMO领域的ESG领导者。我们的工厂使用下一代生物制造技术和清洁能源。我们还成立了一个由首席执行官领导的ESG委员会，以指导全面的ESG战略及其实施，增强我们对可持续性的承诺。。

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

有关无锡生物制品的更多信息，请访问：www.wuxibiologics.com。

Contacts

联系人

Business[email protected]

业务[受电子邮件保护]

Media[email protected]

媒体[受电子邮件保护]

SOURCE WuXi Biologics

来源无锡生物制品